Qiagen N.V.
QGENNYSEHealthcareDiagnostics & Research
As of Oct 26, 2026 close
- Market cap
- $10.47B
- P/E (TTM)
- 25.58
- Forward P/E
- 23.28
- Dividend yield
- 5.50%
- 52-week range
- $32.53$57.82
- Volume (live)
- -
- Avg. volume (3M)
- 4.28M
Qiagen (QGEN) Stock Price & Financial Analysis
Qiagen Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $50.30 - $50.53 |
|---|---|
| 52-Week High | $57.82 |
| 52-Week Low | $32.53 |
| Open | $50.42 |
| Volume (last close) | 4.11M |
| Average Volume (3M) | 4.28M |
| Revenue (TTM) | 2.10B |
|---|---|
| Net Income (TTM) | 409.32M |
| Free Cash Flow (TTM) | 447.70M |
| EPS (TTM) | $1.97 |
| Profit Margin | 19.49% |
| Operating Margin | 25.72% |
| Return on Equity (ROE) | 12.19% |
| Debt to Equity | 0.49 |
| Annual Dividend | $2.76 |
|---|---|
| Dividend Yield | 5.50% |
| Payout Ratio | 140.29% |
| Last Dividend Ex-Date | Jul 7, 2026 |
| Market Cap | 10.47B |
|---|---|
| Shares Outstanding | 207.83M |
| P/E Ratio (TTM) | 25.58 |
| Forward P/E | 23.28 |
| Price to Sales (P/S) | 4.98 |
| Price to Book (P/B) | 3.12 |
| EV/EBITDA | 17.33 |
| 50-Day MA | $43.99 |
|---|---|
| 200-Day MA | $42.52 |
| 1-Year Change | −3.32% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Qiagen at a Glance
As of the Oct 26, 2026 close, Qiagen (QGEN) has a market capitalization of $10.47B. The stock trades at 25.6× trailing earnings, 23.3× forward earnings and 5.0× sales. Over the trailing twelve months it earned $409.32M on revenue of $2.10B (a 19.5% profit margin) and generated $447.70M of free cash flow. Revenue grew 3.0% year over year.
As of its latest reported balance sheet, it holds $768.50M in cash and securities against $1.64B of debt, a net debt position of $875.12M.
Qiagen pays a annual dividend totaling $2.76 per share a year, a 5.50% yield at the Oct 26, 2026 close, with a 140% payout ratio.
The share price is down 3.3% over the past year. At $50.37 (the Oct 26, 2026 close) it sits within its 52-week range of $32.53 to $57.81, above its 200-day moving average of $42.52.
Based on 14 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $48.30, 4.1% below the Oct 26, 2026 close.
Frequently Asked Questions About Qiagen
What is the current stock price for QGEN?
As of the Oct 26, 2026 close, QGEN stock trades at $50.37. The 52-week range is $32.53–$57.82, with a day range of $50.30–$50.53.
What is the P/E ratio for QGEN?
As of the Oct 26, 2026 close, Qiagen's trailing twelve-month (TTM) P/E ratio is 25.6, meaning investors pay $25.6 for every $1 of annual earnings. The forward P/E is 23.3, reflecting analyst expectations for future earnings. Qiagen operates in the Healthcare sector.
Does QGEN pay dividends?
Yes, Qiagen pays a 5.50% annual dividend yield as of the Oct 26, 2026 close ($2.76 per share a year). The trailing twelve-month payout ratio is 140.3%. The most recent ex-dividend date was July 7, 2026.
What do analysts recommend for QGEN?
Based on ratings from 14 professional analysts over the last 90 days, the consensus for QGEN is Hold. The average 12-month price target is $48.30, a 4.1% downside from the Oct 26, 2026 close of $50.37.
What is the market cap of QGEN?
As of the Oct 26, 2026 close, Qiagen's market capitalization is $10.47B, classifying it as a large-cap company. Qiagen operates in the Healthcare sector within the Diagnostics & Research industry.